Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Immunological Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LGALSL drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LGALSL / HSPC159 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 / E. coli options. |
View LGALSL Products |
| Gene Delivery | LGALSL Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View LGALSL Products |
| Benchmark Ab | Anti-LGALSL Recombinant Antibody Recombinant positive control for validation and binding assays. |
View LGALSL Products |
| Validator | LGALSL siRNA Set For target knockdown and functional specificity verification. |
View LGALSL Products |
| Related Target A | LGALS3 (Galectin-3) Major galectin family member; critical for selectivity and off-target safety profiling. |
View LGALS3 Products |
| Related Target B | LGALS1 (Galectin-1) Homologous galectin involved in immune evasion; essential for subfamily counter-screening. |
View LGALS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-target Screening | Homolog panel proteins (LGALS1, LGALS3) strictly verified by mass spectrometry and purity chromatography. |
| Conformational Integrity | HEK293 expressed LGALSL preserving native post-translation modifications and tertiary fold. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as research-grade biosimilars. |
| False Positives in Phenotypic Assays | Validated siRNA sets included for functional knockdown and specificity controls. |
Live LGALSL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LGALSL (HSPC159) therapeutics is in its emerging stages, with research shifting from basic glycobiology to targeted oncology and immunomodulation. As a galectin-like protein that lacks classical carbohydrate-binding activity, the next wave of R&D is targeting its unique protein-protein interaction (PPI) interfaces to disrupt tumor progression and metastasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Academic Institutes & Biotech | Solid Tumors, Metastasis | High-purity extracellular domain (ECD) proteins for binding kinetics (SPR/BLI). |
| Small Molecule (PPI Inhibitor) | Early-stage Biopharma | Inflammatory Diseases, Cancer | High-yield, sequence-verified recombinant LGALSL for high-throughput screening. |
| RNA Therapeutics | Preclinical Consortiums | Fibrotic Disorders | Validated siRNA sets and transfection-ready Lentivirus for target validation. |
Title: LGALSL / HSPC159 Reagents & Drug Discovery Landscape | TarMart Description: Buy high-purity LGALSL (HSPC159) recombinant proteins, biosimilar antibodies, and lentivirus. Explore clinical trends, assays, and counter-screening tools. Keywords: LGALSL protein, HSPC159 target, Galectin-like protein, LGALSL antibody, Galectin counter-screening.